Carrier screening for cystic fibrosis in US genetic testing laboratories: A survey of laboratory directors

Clinical Genetics

Volumn 74, Issue 4, 2008, Pages 367-373

  Kaufman, David J ^a,b   Katsanis, S H ^a   Javitt, G H ^a   Murphy, J A ^a   Scott, J A ^a   Hudson, K L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Cystic fibrosis; Genetic screening; Practice guidelines as topic; Surveys

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CYSTIC FIBROSIS; DNA DETERMINATION; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; LABORATORY PERSONNEL; LABORATORY TEST; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED STATES;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PRACTICE GUIDELINES AS TOPIC; PRENATAL DIAGNOSIS;

EID: 52449105062     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2008.01070.x     Document Type: Article

References (35)

1. Strom CM, Crossley B, Redman JB et al. Cystic fibrosis screening: lessons learned from the first 320,000 patients. Genet Med 2004: 6: 136-140.
2. Cystic Fibrosis Foundation. Patient registry 2005 annual report. Bethesda, MD: Cystic Fibrosis Foundation, 2006.
3. Cystic Fibrosis Mutation Database, 2007. Retrieved April 23, 2007, from http://www.genet.sickkids.on.ca/cftr/app.
4. Richards CS, Grody WW. Prenatal screening for cystic fibrosis: Past, present and future. Expert Rev Mol Diagn 2004: 4: 49-62.
5. National Human Genome Research Institute, 2007. Retrieved April 17, 2007, from http://www.genome.gov/page.cfm?pageID=17515632#beginSearch. Search term =cystic fibrosis. Institute code =HG.
6. National Institutes of Health, 1997. Retrieved April 17, 2007, from http://consensus.nih.gov/1997/1997GeneticTestCysticFibrosis106html.htm.
7. Grody WW, Desnick RJ, Carpenter NJ, Noll WW. Diversity of cystic fibrosis mutation-screening practices. Am J Hum Genet 1998: 62: 1252-1254.
8. Grody WW, Cutting GR, Klinger KW et al. American College of Medical Genetics Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001: 3: 149-154.
9. Richards CS, Bradley LA, Amos J et al. Standards and guidelines for CFTR mutation testing. Genet Med 2002: 4: 379-391.
10. Tsongalis GJ, Belloni DR, Grody WW. Cystic fibrosis mutation analysis: how many is enough? Genet Med 2004: 6: 456-457.
11. Lebo RV, Grody WW. Testing and reporting ACMG cystic fibrosis mutation panel results. Genet Test 2007: 11: 11-31.
12. Chillon M, Casals T, Mercier B et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995: 332: 1475-1480.
13. Lissens W, Mercier B, Tournaye H et al. Cystic fibrosis and infertility caused by congenital bilateral absence of the vas deferens and related clinical entities. Hum Reprod 1996: 11 (Suppl. 4): 55-78.
14. Noone PG, Knowles MR. 'CFTR-opathies': Disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir Res 2001: 2: 328-332.
15. Kerem E, Rave-Harel N, Augarten A et al. A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations. Am J Respir Crit Care Med 1997: 155: 1914-1920.
16. Rohlfs EM, Weinblatt VJ, Treat KJ, Sugarman EA. Analysis of 3208 cystic fibrosis prenatal diagnoses: Impact of carrier screening guidelines on distribution of indications for CFTR mutation and IVS-8 poly-(T) analyses. Genet Med 2004: 6: 400-404.
17. Watson MS, Desnick RJ, Grody WW et al. Cystic fibrosis carrier screening: Issues in implementation. Genet Med 2002: 4: 407-409.
18. Strom CM, Huang D, Buller A et al. Cystic fibrosis screening using the college panel: Platform comparison and lessons learned from the first 20,000 samples. Genet Med 2002: 4: 289-296.
19. Schrijver I, Oitmaa E, Metsplau A, Gardner P. Genotyping microarray for the detection of more than 200 CFTR mutations in ethnically diverse populations. J Mol Diagn 2005: 7: 375-387.
20. Amos JA, Bridge-Cook P, Ponke V, Jarvis MR. A universal array-based multiplexed test for cystic fibrosis carrier screening. Expert Rev Mol Diagn 2006: 6: 15-22.
21. Watson MS, Cutting GR, Desnick RJ et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004: 6: 387-390.
22. Krousal-Wood M, Anderssen HC, Rice J et al. Physicians'perceived usefulness of and satisfaction with test reports for cystic fibrosis (DeltaF508) and factor V Leiden. Genet Med 2003: 5: 166-171.
23. Morgan MA, Driscoll DA, Mennuti MT, Schulkin J. Practice patterns of obstetrician-gynecologists regarding preconception and prenatal screening for cystic fibrosis. Genet Med 2004: 4: 379-391.
24. Andersson HC, Krousel-Wood MA, Jackson KE et al. Medical genetic test reporting for cystic fibrosis (delta F508) and factor V Leiden in North American laboratories. Genet Med 2002: 4: 324-327.
25. Hudson KL, Murphy JA, Kaufman DJ et al. Oversight of U.S. genetic testing laboratories. Nat Biotechnol 2006: 24: 1083-1090.
26. American Association for Public Opinion Research. Standard definitions: final dispositions of case codes and outcome rates for surveys, 4th edn. AAPOR response rate 3. Lenexa, KS: AAPOR, 2006.
27. Amos J, Feldman GL, Grody WW et al. American College of Medical Genetics Technical standards and guidelines for CFTR mutation testing 2006 Edition. Retrieved July 21, 2008, from http://www.acmg.net/Pages/ ACMG_Activities/stds-2002/cf.htm.
28. Sugarman EA, Rohlfs EM, Silverman LM, Alitto BA. CFTR mutation distribution among US Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. Genet Med 2004: 6: 392-399.
29. Zitner A. Lost in translation. Los Angeles Times, F1, 12 May 2003.
30. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: A systematic review of rigorous evaluations. Lancet 1993: 342: 1317-1322.
31. Grimshaw JM, Shirran L, Thomas R et al. Changing provider behavior: And overview of systematic reviews of interventions. Med Care 2001: 39: II2-II45.
32. Grilli R, Lomas J. Evaluating the message: The relationship between compliance rate and the subject of practice guideline. Med Care 1994: 32: 202-213.
33. Oosterhuis WP, Brun DE, Watine J, Sandberg S, Horvath AR. Evidence based guidelines in laboratory medicine: Principles and methods. Clin Chem 2004: 50: 806-818.
34. Palomaki GE. Prenatal screening for cystic fibrosis: An early report card. Genet Med 2004: 6: 115-116.
35. Guttmacher AE, Porteous ME, McInerney JD. Educating health-care professionals about genetics and genomics. Nat Rev Genet 2007: 8: 151-157.